Evolent Health (EVH) Q3 FY2026 earnings: revenue $725 million, up 51.3% on the year
Evolent Health, Inc. (EVH) reported revenue of $725 million for Q3 FY2026, the quarter ended 30 September 2026, up 51.3% on the same quarter a year earlier. Net income was -$24 million, and diluted earnings per share $-0.21. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.
Revenue
$725 million
+51.3% on the year · +11.2% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
-0.9%
0.2% a year earlier
Q4 FY2024Q3 FY2026
Net income
-$24 million
Q4 FY2024Q3 FY2026
Diluted EPS
-$0.21
Q4 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 1 narrowed, 1 new, 1 kept.
Revenue rose year on year: Revenue was $725,367 thousand against $479,533 thousand a year earlier. Net loss attributable to common shareholders was $23,566 thousand, or $0.21 per share, against $26,930 thousand.
Adjusted EBITDA fell, margin 4.7%: Adjusted EBITDA was $34,257 thousand, a 4.7% margin, against $38,955 thousand and 8.1% a year earlier. Nine-month Adjusted EBITDA was $84,374 thousand against $113,362 thousand.
Full-year Adjusted EBITDA range raised: Full-year 2026 revenue range reiterated at $2.6 billion to $2.7 billion. Adjusted EBITDA range raised to $130.0 million to $135.0 million.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
26.4
-9.3
15.8
+66.8%
Cash from investing
-7.1
-6.7
-8.8
Cash from financing
-4.6
-11.0
-41.8
Depreciation and amortisation
21.5
21.6
23.6
-0.3%
-9.0%
Share-based compensation
14.8
15.2
14.7
-2.6%
+0.8%
Diluted shares, weighted
113m
113m
114m
+0.5%
-0.9%
Shares outstanding at period end
113m
113m
112m
+0.0%
+1.3%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
373
383
842
-2.7%
-55.7%
Redeemable equity
0.0
0.0
0.0
Short-term borrowings
n/a
n/a
5.1
Debt
969
966
1,055
+0.3%
-8.1%
Operating lease liabilities
2.2
2.4
4.4
-7.3%
-49.3%
Other liabilities
618
620
547
-0.4%
+12.9%
Total liabilities and equity
1,962
1,972
2,453
-0.5%
-20.0%
Fixed assets
82.5
81.9
80.1
+0.7%
+3.0%
Goodwill
694
694
1,075
-0.0%
-35.4%
Intangible assets
539
554
624
-2.8%
-13.6%
Cash and equivalents
148
116
117
+28.1%
+27.1%
Receivables
443
449
387
-1.4%
+14.5%
Other assets
55.0
76.3
171
-27.9%
-67.8%
Total assets
1,962
1,972
2,453
-0.5%
-20.0%
Questions
What was Evolent Health's revenue in Q3 FY2026?
Evolent Health (EVH) reported revenue of $725 million for Q3 FY2026, the quarter ended 30 September 2026, up 51.3% on the same quarter a year earlier.
How much did Evolent Health earn in Q3 FY2026?
Net loss for Q3 FY2026 was $24 million, and the diluted loss per share $0.21.
When did Evolent Health report Q3 FY2026 results?
Evolent Health filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.
Each quarter as filed, linked to its filing. Read moreA quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.